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Highlights 
 Interethnic differences in meropenem pharmacokinetics are absent. 
 Creatinine clearance remains the strongest determinant of meropenem dosing. 
 This study needs to be repeated for other antibiotics. 
ABSTRACT 
Currently there are no pharmacokinetic (PK) data to guide antibiotic dosing in critically ill Australian 
Indigenous patients with severe sepsis. This study aimed to determine whether the population 
pharmacokinetics of meropenem were different between critically ill Australian Indigenous and critically 
ill Caucasian patients. Serial plasma and urine samples as well as clinical and demographic data were 
collected over two dosing intervals from critically ill Australian Indigenous patients. Plasma meropenem 
concentrations were assayed by validated chromatography. Concentration–time data were analysed 
with data from a previous PK study in critically ill Caucasian patients using Pmetrics. The population PK 
model was subsequently used for Monte Carlo dosing simulations to describe optimal doses for these 
patients. Six Indigenous and five Caucasian subjects were included. A two-compartment model 
described the data adequately, with meropenem clearance and volume of distribution of the central 
compartment described by creatinine clearance (CLCr) and patient weight, respectively. Patient ethnicity 
was not supported as a covariate in the final model. Significant differences were observed for 
meropenem clearance between the Indigenous and Caucasian groups [median 11.0 (range 3.0–14.1) L/h 
vs. 17.4 (4.3–30.3) L/h, respectively; P < 0.01]. Standard dosing regimens (1 g intravenous every 8 h as a 
30-min infusion) consistently achieved target exposures at the minimum inhibitory concentration 
breakpoint in the absence of augmented renal clearance. No significant interethnic differences in 
meropenem pharmacokinetics between the Indigenous and Caucasian groups were detected and CLCr 
was found to be the strongest determinant of appropriate dosing regimens. 
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1. Introduction 
Sepsis has been a major health issue in the Australian Indigenous population and is associated with high 
morbidity and mortality rates [1–3]. It remains one of the greatest health concerns; ca. 60% of deaths in 
the Indigenous patient population of the largest Central Australian remote hospital were related to 
infection in comparison with 25% in the non-Indigenous patient population from 2000–2005. Fifty-six 
per cent of the infection-related deaths were attributed to bacterial sepsis [4]. 
 
Meropenem is a broad-spectrum antibiotic commonly used in the intensive care unit (ICU) [5]. Its 
pharmacokinetic/pharmacodynamic (PK/PD) properties show a time-dependent bacterial kill 
characteristic with a target of maintaining the free drug concentration above the minimum inhibitory 
concentration (MIC) for 40% of the dosing interval (>40%fT>MIC). [6]. However, significant changes in the 
volume of distribution (Vd) and drug clearance observed in critically ill patients can alter the possibility of 
achieving this target [7]. These PK changes are difficult to predict, especially in the absence of 
therapeutic drug monitoring. 
 
Conventional dosing guidelines are usually followed in critically ill Indigenous patients; however, a 
recent systematic review suggested PK differences between ethnicities for some antibiotics [8]. Indeed, 
young, healthy Indigenous adults are reported to have 30% less nephrons than non-Indigenous 
comparators as well as having a mean kidney volume that is 27% greater [9]. From an anthropometric 
perspective, the Australian Indigenous have a lower body mass, higher central fat and slimmer limbs 
[10]. Furthermore, they were shown to have a similar allele frequency to South Asians for some 
cytochrome P450 enzymes [11]. Whether these physiological differences affect meropenem 
pharmacokinetics in the acute setting is unknown. Currently there are no available data on the antibiotic 
pharmacokinetics of critically ill Indigenous patients in Australia. 
 
This study aimed to compare the population pharmacokinetics of meropenem in Australian Indigenous 
patients with severe sepsis and critically ill Caucasian patients with sepsis. 
 
2. Materials and methods 
2.1. Institution where the work was carried out 
This work was carried out at the Department of Intensive Care Medicine of Alice Springs Hospital (Alice 
Springs, Northern Territory, Australia). 
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 2.2. Setting 
This was a prospective, observational cohort study investigating the pharmacokinetics of meropenem. 
Ethical approval was obtained from local (Central Australian Human Research Ethics Committee) and 
university (The University of Queensland Human Research Ethics Committee) ethics committees. 
 
2.3. Study population 
The inclusion criteria were: (i) Australian Indigenous; (ii) ≥18 years of age; (iii) confirmed or suspected 
severe sepsis within the previous 48 h; (iv) prescribed meropenem; and (v) an arterial line in situ. The 
exclusion criteria were: (i) creatinine clearance (CLCr) <15 mL/min; (ii) requiring haemodialysis or 
continuous renal replacement therapy; and (iii) pregnancy. 
 
2.4. Study protocol 
The dose of meropenem (DBL Meropenem®; Hospira Australia, Melbourne, VIC, Australia) was 
determined by the treating clinicians and was made up in 100 mL of sodium chloride 0.9% and infused 
intravenously over 30 min. Ten blood samples were collected in 2 mL lithium heparin tubes from the 
existing arterial line over one dosing interval at 0, 15, 30, 45, 60, 90, 120, 180, 360 and 480 min from 
initiation of infusion. A second set of samples following the same regimen was obtained the next day. 
Demographics, clinical information and routine laboratory test results performed on the study days 
were also collected. 
 
2.5. Sample handling and storage 
Blood samples were placed in a drug refrigerator at 2–8 C immediately after sampling. Samples were 
then centrifuged at 5000 rpm for 6 min within 8 h of collection. Both plasma and urine samples were 
aspirated into cryovials and were stored in a freezer at –70 C. Samples were packed with dry ice and 
were freighted to the Burns Trauma & Critical Care Research Centre, The University of Queensland 
(Brisbane, QLD, Australia) for drug assay. 
 
2.6. Drug assay 
Plasma concentrations of meropenem were determined by validated high-performance liquid 
chromatography with ultraviolet detection (HPLC-UV) on a Shimadzu Prominence instrument. Sample 
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analysis was conducted in batches with calibration standards and quality controls in which batch 
acceptance criteria were applied. Before the chromatographic analysis was performed, acetonitrile was 
added to 100 L aliquots of plasma combined with internal standard (cefotaxime) to precipitate proteins. 
Following centrifugation, the supernatant was isolated and was washed with dichloromethane to 
remove acetonitrile and lipophilic components. Following centrifugation, the upper layer was isolated 
for chromatographic analysis. 
 
For the chromatography, the stationary phase was a Waters XBridge C18 2.1  50 mm column. The 
mobile phase was 4% acetonitrile/96% 50 mM phosphate buffer at pH 2.5 delivered isocratically. The 
eluent was monitored at 304 nm. For sample validation, the calibration curve was linear with a 
weighting of 1/x2 over the range 0.2–100 mg/L. The precision and accuracy at the lower limit of 
quantification were ≤5.9%. The assay was validated against matrix effects (precision and accuracy within 
4% at high and low concentrations). The assay’s precision and accuracy was determined both within-day 
and between-day and was within 6.5% at all three concentrations tested. 
 
2.7. Population pharmacokinetic modelling 
Data collected from six Indigenous patients’ plasma samples were combined with five critically ill 
Caucasian patients from a previously published study with a similar study protocol including 
concentration–time data that were available to us in order that ethnicity of the patient group could be 
tested regarding whether it significantly influences meropenem pharmacokinetics as a covariate [12]. A 
two-compartment model was developed with Nonparametric Adaptive Grid (NPAG) algorithm using the 
Pmetrics® software package [13] for R® v.3.2.2. Demographic and clinical data [age, ethnicity, sex, weight, 
CLCr, Sequential Organ Failure Assessment (SOFA) score, serum albumin, serum creatinine and 
vasopressor therapy requirement] that may influence meropenem pharmacokinetics were tested for 
inclusion in the model as covariates. If the covariate inclusion resulted in an improvement in the log 
likelihood (P < 0.05) and/or improved the goodness-of-fit plots, they were included in the model. 
 
2.8. Model diagnostics 
Model evaluation was assessed by visual assessment of the goodness of fit of the observed–predicted 
plots and the coefficient of determination of the linear regression of the observed–predicted values (r2 
close to 1, intercept close to 0) from each run. The predictive performance was assessed on mean 
prediction error (bias) and the mean biased-adjusted squared prediction error (imprecision) of the 
population and individual posterior predictions. 
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2.9. Dosing simulations 
The probability of target attainment (PTA) was obtained from Monte Carlo simulation (n = 1000) in 
Pmetrics®. This assesses the likelihood of achieving 40%fT>MIC (considering 2% protein binding) over the 
first 24 h for various dosing regimens and levels of CLCr for MICs between 0.125 mg/L and 32 mg/L. 
Results were then used to make dosing recommendations based on the lowest dosing regimen that still 
achieved 90% PTA. 
 
2.10. Statistical analysis 
Continuous data were presented as the median (range) and categorical data were presented as counts 
(%). Statistical differences were assessed for demographic data and pharmacokinetic parameters 
between the Indigenous and Caucasian population using Pearson’s 2 and Mann–Whitney U-tests in R®. 
A P-value of <0.05 was considered statistically significant. 
 
3. Results 
Six Indigenous and five Caucasian patients were included in the study, providing 216 plasma samples for 
analysis. The demographics and clinical information are presented in Table 1. In general, the Indigenous 
group was younger, had a lower CLCr and had more patients requiring vasopressor therapy, although not 
statistically significant. They also had significantly higher SOFA scores. 
 
3.1. Population pharmacokinetic model building 
A two-compartment model was found to describe the data adequately, with CLCr and patient’s actual 
body weight being the only tested covariates that significantly improved the PK model. The final model 
is described as: 
 
        
    
   
 
          
  
  
 
    
 
 
where TVCL is the typical value of meropenem clearance in the population (includes Indigenous and 
non-Indigenous patients), CL is the population parameter estimate of meropenem clearance, TVVc is the 
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typical value of Vc, Vc is the population parameter estimate of the volume of the central compartment, 
and wt is total body weight. The goodness of fit for the individual- and population-predicted versus 
observed plots were acceptable (Fig. 1). 
 
The combined and comparative population PK parameter estimates from the two-compartment model 
are also presented in Table 1. Clearance was significantly lower for the Indigenous patients compared 
with the Caucasian patients (P = 0.004). However, this difference in clearance was well described by CLCr 
but not by ethnicity, hence ethnicity was not included as a covariate in the final model. 
 
3.2. Dosing simulations 
Dosing recommendations for specific CLCr values against different MICs were performed using the 
results of PTA for various regimens (different doses, dosing intervals, and intermittent and continuous 
infusions) and are presented in Table 2. Continuous infusion of the same daily dose achieved higher PTA 
compared with 30-min infusion regimens, whereas an increase in CLCr resulted in a decline in PTA. 
 
4. Discussion 
To our knowledge, this is the first study to investigate the population pharmacokinetics of meropenem 
in Australian Indigenous patients with severe sepsis. These results suggest that meropenem 
pharmacokinetics were not significantly different in Australian Indigenous patients relative to Caucasian 
comparators. 
 
The principal difference between the two groups related to drug clearance, which was adequately 
described by patient renal function defined as CLCr. This demonstrates that renal function remains the 
most important determinant of meropenem pharmacokinetics, and dosing regimens should be guided in 
accordance with the patient’s CLCr. Although the median CLCr between the two groups was not 
significantly different, two of the Indigenous patients had a CLCr of 15–20 mL/min, which may have 
contributed to the significant difference in meropenem clearance observed between the two groups. 
The estimated meropenem clearance (median 11.0 L/h) in the Indigenous patients was also similar to 
results from previous studies in septic and critically ill patients with comparable CLCr (meropenem 
clearance 7.8–11.5 L/h [14–16]). Of note, the Indigenous group in the current study was 10–30 years 
younger compared with patients in the previous studies [14–16], although the level of renal function 
was similar. This observation supports previous data reporting the significantly higher prevalence of 
chronic kidney diseases and poorer renal function in the Australian Indigenous population compared 
with age-matched Caucasians [17]. 
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 The absence of interethnic differences in meropenem pharmacokinetics in this study aligns with 
previous observations demonstrating that interethnic PK differences are unlikely in antibiotics that are 
predominantly eliminated via glomerular filtration [8]. 
 
Importantly, in this study we have found a large interindividual variability in meropenem 
pharmacokinetics in the studied patients. Significant fluctuations in drug clearance and Vd are common 
in critically ill patients [18] and have been reported in other studies investigating meropenem 
pharmacokinetics [14,16]. These studies generally conclude that this profound variability in 
pharmacokinetics increases the likelihood of subtherapeutic concentrations or drug accumulation and 
associated toxicities. 
 
The dosing simulations aiming for the 40%fT>MIC target revealed that a regimen of 500 mg twice daily 
gives an acceptable PTA for pathogens with an MIC of 2 mg/L (clinical breakpoint for most non-resistant 
Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter spp., Haemophilus influenzae 
and Moraxella catarrhalis) in patients with CLCr of 21–50 mL/min. However, 1 g three times daily is 
needed in patients with CLCr of 100 mL/min; 1 g four times daily is likely required in a patient with CLCr of 
130 mL/min. 
 
Continuous infusion, however, consistently achieved better PK/PD target attainment, as has been shown 
in previous studies [19]. As expected, with increasing CLCr, higher daily doses or use of continuous 
infusion is required to achieve PK/PD targets. We would note that a standard dose of 1 g three times 
daily would be insufficient for patients with CLCr > 100 mL/min for pathogens with a MIC of 2 mg/L. 
 
This study has some limitations. Specifically, the small sample size limited the power to detect other 
potential covariates affecting meropenem pharmacokinetics and also to determine whether failure to 
achieve PK/PD targets was associated with an altered clinical outcome. Second, samples were collected 
on two dosing intervals and so may not have been able to describe all of the perturbations in 
pharmacokinetics that occurred over the duration of treatment. Finally, samples were not collected 
from the site of infection (e.g. epithelial lining fluid in pneumonia) and therefore the dosing 
recommendations relate to achievement of target exposures in blood only. 
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5. Conclusions 
This study has highlighted that CLCr remains the strongest determinant of meropenem pharmacokinetics 
in patients with severe sepsis. Although no interethnic differences in meropenem pharmacokinetics 
between Indigenous and Caucasian Australians were demonstrated in this study, this may be, at least in 
part, due to the low number of patients recruited and high interindividual PK variability. 
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Fig. 1. Diagnostic plots for the final covariate model. Observed versus population-predicted 
concentrations (left) and individual-predicted concentrations (right) in plasma. Data are presented in 
mg/L. 
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Table 1 
Demographics, clinical data and pharmacokinetic parameter estimates from two-compartment model a 
 Total (n = 11) Indigenous (n = 6) Caucasian (n = 5) P-value b 
Age (years) 48 (22–76) 45 (22–76) 55 (29–69) 0.329 
Female sex 6 (55) 4 (67) 2 (40) 0.782 c 
Weight (kg) 80 (60–110) 73 (60–104) 80.0 (60–110) 0.519 
Height (cm) 170 (157–185) 167.5 (157–176) 170 (165–185) 0.231 
BMI (kg/m2) 26.6 (23.7–34.1) 26.4 (23.7–34.1) 26.6 (20.8–30.3) 1.000 
SCr (mol/L) 73 (37–301) 76 (37–301) 73 (43–109) 1.000 
CLCr (mL/min) 105.7 (15.5–164.0) 98.2 (15.5–164.0) 105.7 (19.6–144.3) 0.662 
Albumin (g/L) 32 (20–39) 32 (26–39) 28 (18–37) 0.782 
Vasopressors 8 (73) 6 (100) 2 (40) 0.122 c 
SOFA score 10 (2–15) 11 (10–15) 3 (2–11) 0.007 d 
Vc (L) 13.6 (9.7–18.4) 11.0 (9.8–17.0) 15.3 (9.7–18.4) 0.082 
CL (L/h) 14.1 (3.0–30.3) 11.0 (3.0–14.1) 17.4 (4.3–30.3) 0.004 d 
Kcp (h
–1) 1.49 (0.57–5.32) 1.25 (0.57–1.73) 1.91 (0.69–5.32) 0.247 
Kpc (h
–1) 2.38 (0.77–16.6) 1.41 (1.07–2.37) 5.89 (0.77–16.6) 0.017 d 
BMI, body mass index; SCr, serum creatinine; CLCr, creatinine clearance; SOFA, Sequential Organ Failure 
Assessment; Vc, central volume of distribution; CL, meropenem clearance; Kcp, distribution rate constant 
from central to peripheral compartment; Kpc, distribution rate constant from peripheral to central 
compartment. 
a Data are presented as the median (range) or n (%). 
b The P-value was obtained by Mann–Whitney U-test unless otherwise specified. 
c The P-value was obtained by Pearson’s 2 test. 
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d Figures in bold are statistically significant (P < 0.05). 
 
 
Table 2 
Dose recommendations for critically ill patients 
CLCr (mL/min) MIC  0.25 mg/L MIC = 2 mg/L 
20 0.5 g q24h 0.5 g q24h 
21–50 0.5 g q12h 0.5 g q12h 
51–100 0.5 g q8h 1 g q8h 
101–130 1 g q8h 1 g q6h or 3 g CI 
131–170 1 g q8h 1 g q6h or 3 g CI 
CLCr, creatinine clearance; MIC, minimum inhibitory concentration; q24h, every 24 h; q12h, every 12 h; 
q8h, every 8 h; q6h, every 6 h; CI, continuous infusion. 
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